Pfizer withdraws extension of therapeutic indication for DME

Article

Pfizer has notified the European Medicines Agency (EMA) that it will withdraw it's application for an extension on the therapeutic indication for Macugen.

Pfizer has notified the European Medicines Agency (EMA) that it will withdraw it's application for an extension on the therapeutic indication for Macugen.

The pegaptanib sodium, 0.3 mg solution for injection is currently authorized as a neovascular, wet age-related macular degeneration (AMD) treatment.

Pfizer had recently submitted an application to extend the marketing authorization of Macugen.

The firm's reason for withdrawing the application is that the EMA's Committee for Medicinal Products for Human Use (CHMP) believes a positive benefit-risk balance cannot be conducted with the information provided so far.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.